ABL Bio secures $55 million from Eli Lilly to accelerate Grabody platform development

The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas

Biohaven reports Phase 2 depression trial results

Despite some promising subgroup signals, the company indicated it will not pursue further psychiatric trials

INOVIO’s DNA therapy for rare throat disease gets FDA review

INOVIO remains confident in the therapy’s benefits and intends to meet with the FDA to discuss maintaining eligibility under this pathway

WuXi Biologics wins HERA 2025 Award for outstanding ESG disclosure

The company views ESG reporting as a strategic tool to build trust with clients, investors, regulators, and stakeholders worldwide

Lupin and Gan & Lee enter exclusive licensing deal for novel GLP-1 receptor agonist

Lupin has bolstered its diabetes and obesity portfolios by securing an agreement for Bofanglutide, a GLP-1 receptor agonist developed by Gan & Lee Pharmaceuticals

Intas and IntegriMedical to launch India’s first needle-free injection system for IVF and gynaecology

Intas becomes the first and only company in India to offer IVF and gynecology therapies with needle-free injections

SN Bioscience’s SNB-101 wins FDA orphan drug designation for gastric cancer

The drug, currently in a phase 1b/2 clinical trial for small cell lung cancer, is a polymer nanoparticle formulation of SN-38

ENHERTU gains first-ever nod in China for metastatic breast cancer

The approval follows results from the DESTINY-Breast06 phase 3 trial, which showed ENHERTU significantly extended progression-free survival compared to chemotherapy

Govt cancels registration of popular cosmetic product over misleading claims

The cancellation underscores the regulator’s strict stance against misleading cosmetic claims

US House passes Bill reauthorizing FDA rare disease incentive program